Novo Nordisk fortsætter onsdag med at falde, efter at aktien tirsdag lukkede med det største procentmæssige fald nogensinde.

Hans farvel markerer enden på en æra i Novo Nordisks historie. Finansanalytikere kalder kursfaldet dramatisk, men ikke helt ...

Shares in Asia are mixed after the U.S. and China ended their latest round of trade talks without a deal. U.S, futures edged ...

NEW YORK — Wall Street’s record-breaking, weeklong run ran out of momentum on Tuesday. The S&P 500 slipped 0.3% for its first drop after closing at an all-time high in six successive days. The Dow ...

Novo Nordisk shares plunged more than 20% on the 29th (local time) in New York and Denmark on the 29th (local time) due to the announcement of a slowdown in sales growth of the obesity drug "Wegovy".

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk’s success in recent years has been driven by its popular semaglutide-based GLP-1 products — Ozempic (injection) and Rybelsus (oral) for T2D, and Wegovy for obesity.

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy collaboration turned on the telehealth provider’s selling of a copycat weight-loss ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

Novo Nordisk says Wegovy has about 200,000 weekly prescriptions in the U.S., where it brought in nearly $1.9 billion in first-quarter sales.